This site is intended for healthcare professionals

Secukinumab gets EC approval for treating hidradenitis suppurativa

Time : 2nd of June 2023 04:49:25 PM Physician/Medicine,Pharma News,Dermatology

Cosentyx® (secukinumab) became the only new biologic approved in the last decade for this condition. It provided rapid symptom relief by week 4, with increasing response rates for up to a year. The safety profile of the drug was already established across other indications. The drug is also used fot treating plaque psoriasis, spondylitis, spondyloarthritis, and arthritis.

First topical gene therapy gets FDA approval

Time : 23rd of May 2023 11:51:07 AM Physician/Medicine,Pharma News,Dermatology

Vyjuvek is a herpes simplex virus type 1 vector-based therapy that can be used for treating wounds in individuals aged 6 months and older suffering from dystrophic epidermolysis bullosa with COL7A1 gene mutations. It improved wound healing from this skin condition with 100% wound closure in 24 weeks. Itching, redness, chills and cough were commonly seen adverse reactions.

CDC reports drug-resistant ringworm cases

Time : 17th of May 2023 10:29:38 AM Physician/Medicine,Dermatology

The two cases reported in two unrelated people are the first ever cases recorded in the US. The patients had severe cases of topical tinea that did not resolve with initial treatment. However, the agency said there was not much threat to public health. Trichophyton indotineae, a ringworm-causing, highly transmissible, resistant fungus, caused these infections.

FDA places hold on a trial on alopecia drug

Time : 8th of May 2023 10:21:11 AM Pharma News,Dermatology

Deuruxolitinib, a selective oral JAK1 and JAK2 inhibitor, caused pulmonary embolism at 12 mg twice daily dose in study participants. As a result, the agency placed a partial hold and suggested participants take this dose to discontinue the drug. On the other hand, no thrombotic events were seen with an 8 mg twice daily dose. The drug received Breakthrough Therapy designation.
  Sun Pharma

Supplements may contain hidden allergens

Time : 3rd of May 2023 07:51:05 AM Physician/Medicine,Pharma News,Nutrition & Fitness,Dermatology

Hidden allergens in supplements can range from coloring agents to vitamins in hair products, as per a study. Dermatologists also say that patients do not discuss the dietary supplements they consume, making it challenging to identify potential allergens. Red pigment carmine from beetles, gelatin, certain vitamins, some herbs and spices are some of the culprits.
  US Today News

FDA approves a new treatment to correct cheek wrinkles

Time : 27th of April 2023 11:56:35 AM Dermatology

Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) is an original and the first PPLA collagen stimulator approved for the correction of wrinkles and fine lines in the full cheek area. It can be used in patients with healthy immune systems. People on therapy had sustained aesthetic improvements, where 94% showed improvements in wrinkles and skin glow even at two years.

Squamous cell carcinoma after breast implants is rare

Time : 26th of April 2023 10:15:14 AM Oncology,General Surgery,Dermatology

The incidence of SCC in women after breast reconstruction from implants was very low, as per analysis. Only a few cases have been identified after long latency periods after the procedure. But an increased incidence of breast implant-associated anaplastic large-cell lymphoma was observed. Women should be counselled about these risks but not discouraged from getting implants.
  Twitter @JAMASurgery

EU approves ruxolitinib cream to treat vitiligo

Time : 24th of April 2023 12:19:10 PM Physician/Medicine,Pharma News,Dermatology

Opzelura® (ruxolitinib) Cream became the only approved treatment for treating individuals aged 12 years and above with non-segmental vitiligo with facial involvement. The selective JAK1/JAK2 inhibitor caused improvements in the repigmentation of the face and total body compared to a vehicle in phase 3 trials. Application site acne was the most common side effect.
  Business Wire

USPSTF issues updated screening guidelines for skin cancer

Time : 21st of April 2023 12:26:57 PM Oncology,Dermatology

They suggest there was no evidence to advise for or against screening people without symptoms using visual skin exams. It does not apply to people at a higher risk of skin cancer. Clinicians are asked to use the ABCDE rule while looking at skin lesions. Treatment options include surgical removal of the primary tumor and immuno- or targeted therapies for advanced melanoma.
  US Preventive Services Task Force

FDA approves the first sweat control patch for axillary hyperhidrosis

Time : 17th of April 2023 11:40:34 AM Physician/Medicine,Pharma News,Dermatology

Brella™ is a 3-Minute SweatControl Patch that adults can wear underarms to control excessive underarm sweat due to primary axillary sweating. It is a fast, need-free, non-invasive, affordable, and aluminium-free treatment option, producing results that last 3 to 4 months, as per studies. The patch improved the quality of life without causing severe adverse events.